AZNDrug Launch•prnewswire•
TROP2-Targeted Antibody-Drug Conjugates Set to Transform NSCLC Treatment Market by 2040 | DelveInsight
Sentiment:Positive (65)
Summary
(NASDAQ:AZN) According to DelveInsight's analysis, the TROP2 ADC in the NSCLC market landscape is expected to evolve significantly, driven by new opportunities, following the approval of DATROWAY. Additionally, the expected launch of TROP2 ADCs in NSCLC, such as TRODELVY (sacituzumab govitecan)...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 10, 2025 by prnewswire